(Jerusalem Comprehensive Electric) Israel will vaccinate the fourth dose of crown disease for people over 60 years of age and medical personnel to strengthen the infection of the response to Omiko strains.

Israeli Prime Minister Bernete announced on Sunday that the country's Ministry of Health has approved the fourth dose of coronary vaccine for people over 60 years of age and medical staff.Four months.

Bened described that the fourth dose vaccine can provide the Israelites with "new layer of protection".He said: "A new wave of epidemic caused by Omikon is here, we must protect ourselves."

Last Thursday, Israel has approved people with low immunity and residents of elderly nursing homes.The four -dose vaccine has become one of the first -doses of additional additional agents.

The recent sharp rebound in the Israeli epidemic has a sharp rebound. There are 4206 new crown diagnosis cases on Sunday, an increase of 195%from a week ago. It is expected that this number will reach a new high in the next three weeks.

Beline pointed out that the number of people infected with Israel may increase to 50,000 daily infections, and urged all adults and children to vaccine.

Ash, director of the Ministry of Health of Israel, pointed out that the continued rising cases of Omikon may cause Israel to achieve group immunity.He said in an interview with the radio earlier Sunday: "The number of infections must be very high in order to achieve group immunity. This is possible, but we do not want to achieve group immunity through more people.Do this. "

So far, 6.56 million of the 9.4 million people in Israel have vaccinated at least one dose of vaccine, about 5.98 million people have completed two doses, and about 4.24 million people have vaccinated the third dose.Essence

Approval of crown disease oral medication treatment for patients with mild to middle disease

In addition, the Israeli Ministry of Health also approves the crown disease developed by Merck in the United StatesMolnupiravir, which is used for the treatment of patients with mild to mediocrine.This is the second oral medicine used in Israel after Fiefir's PaxLovid.

The Israeli Ministry of Health issued a statement on Sunday saying that Monabeville is aimed at preventing viruses from copying in the body. It is expected that its curative effect will not be affected by the coordinates of coronary diseases.Treatment of Rong poison strains.

The ministry has signed a purchase agreement with Merke, and the first batch of drugs are expected to arrive in Israel within a few days.

Israel will use Monillai Laevir to treat people 18 years and above. Patients should start medication three to five days after symptoms and take them for five consecutive days.

Studies show that this drug can reduce the hospitalization rate and mortality rate of crown disease by 30%.